Published in Ann Oncol on April 03, 2012
Diagnosis and treatment of primary CNS lymphoma. Nat Rev Neurol (2013) 1.56
Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation. Haematologica (2013) 0.94
Primary CNS lymphoma. Curr Hematol Malig Rep (2014) 0.85
Recent advances in treatment of primary central nervous system lymphoma. Curr Treat Options Oncol (2013) 0.81
High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma-a randomized phase III trial (MATRix). BMC Cancer (2016) 0.78
High-dose chemotherapy and autologous stem cell transplantation for secondary central nervous system lymphoma: many are called, but few are chosen. Haematologica (2013) 0.75
Concomitant systemic and central nervous system non-Hodgkin lymphoma: the role of consolidation in terms of high dose therapy and autologous stem cell transplantation. A 60-case retrospective study from LYSA and the LOC network. Haematologica (2015) 0.75
Isolated recurrence of secondary CNS lymphoma: case report and literature review. J Neurol Surg Rep (2014) 0.75
High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study. Bone Marrow Transplant (2017) 0.75
Methotrexate plus idarubicin improves outcome of patients with primary central nervous system lymphoma. Oncotarget (2017) 0.75
Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer (1988) 4.03
Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood (1996) 2.08
Treatment of systemic sclerosis with autologous haemopoietic stem cell transplantation. Lancet (1997) 1.76
Endoscopic diagnosis of acute intestinal GVHD following allogeneic hematopoietic SCT: a retrospective analysis in 175 patients. Bone Marrow Transplant (2011) 1.73
Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia (2005) 1.70
[Polyneuropathy following methaqualone (preliminary note)]. Nervenarzt (1973) 1.64
Remission of refractory Crohn's disease by high-dose cyclophosphamide and autologous peripheral blood stem cell transplantation. Aliment Pharmacol Ther (2012) 1.47
A new Puumala hantavirus subtype in rodents associated with an outbreak of Nephropathia epidemica in South-East Germany in 2004. Epidemiol Infect (2006) 1.43
An aerobic exercise program for patients with haematological malignancies after bone marrow transplantation. Bone Marrow Transplant (1996) 1.38
Fermi observations of high-energy gamma-ray emission from GRB 080916C. Science (2009) 1.37
Autologous hematopoietic stem cell transplantation for autoimmune diseases. Bone Marrow Transplant (2005) 1.37
[Methodological openness as the basis of integrative psychotherapy]. Psychother Psychosom Med Psychol (2000) 1.34
Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome. Bone Marrow Transplant (2004) 1.34
Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis (2004) 1.30
2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer (2001) 1.30
Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia (2003) 1.30
Non-intensive treatment with low-dose 5-aza-2'-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients. Bone Marrow Transplant (2009) 1.29
IL-10 induces DNA binding activity of three STAT proteins (Stat1, Stat3, and Stat5) and their distinct combinatorial assembly in the promoters of selected genes. FEBS Lett (1996) 1.29
Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia. Leukemia (2011) 1.24
Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings. Leukemia (2012) 1.23
Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET? Ann Oncol (2005) 1.21
A limit on the variation of the speed of light arising from quantum gravity effects. Nature (2009) 1.20
Detection of cytomegalovirus DNA in CD34+ cells from blood and bone marrow. Blood (1995) 1.19
BCL-2/JH rearrangements in circulating B cells of healthy blood donors and patients with nonmalignant diseases. J Clin Oncol (1996) 1.17
Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. J Immunol (1996) 1.13
[Clarithromycin for monotherapy of B-cell MALT lymphoma?]. Ophthalmologe (2013) 1.08
Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the Chronic Leukemia Working Party of the EBMT. Bone Marrow Transplant (2009) 1.07
Interleukin-10 increases Bcl-2 expression and survival in primary human CD34+ hematopoietic progenitor cells. Blood (1996) 1.07
Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy. Ann Oncol (2007) 1.06
Lymphocyte reconstitution following allogeneic hematopoietic stem cell transplantation: a retrospective study including 148 patients. Bone Marrow Transplant (2007) 1.06
Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis (2001) 1.02
Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis. Bone Marrow Transplant (2004) 1.01
Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives. Bone Marrow Transplant (2004) 1.00
Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma. Leukemia (2011) 0.99
The JAK-STAT pathway: signal transduction involved in proliferation, differentiation and transformation. Leuk Lymphoma (1998) 0.99
T cells from renal cell carcinoma patients exhibit an abnormal pattern of kappa B-specific DNA-binding activity: a preliminary report. Cancer Res (1994) 0.98
Inhibition of NF-kappa B activity in human T lymphocytes induces caspase-dependent apoptosis without detectable activation of caspase-1 and -3. J Immunol (1999) 0.98
Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting. Bone Marrow Transplant (2009) 0.98
A novel pedigree with heterozygous germline RUNX1 mutation causing familial MDS-related AML: can these families serve as a multistep model for leukemic transformation? Leukemia (2009) 0.97
Surveillance of nosocomial infections in adult recipients of allogeneic and autologous bone marrow and peripheral blood stem-cell transplantation. Bone Marrow Transplant (2003) 0.97
Longitudinal follow-up of nutritional status and its influencing factors in adults undergoing allogeneic hematopoietic cell transplantation. Bone Marrow Transplant (2012) 0.97
T cells infiltrating non-Hodgkin's B cell lymphomas show altered tyrosine phosphorylation pattern even though T cell receptor/CD3-associated kinases are present. J Immunol (1995) 0.96
Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly. Ann Oncol (2011) 0.95
High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study. Ann Oncol (2008) 0.95
Transfusion-transmitted hepatitis E in Germany, 2013. Euro Surveill (2014) 0.95
Selective cytokine gene expression in renal cell carcinoma tumor cells and tumor-infiltrating lymphocytes. Int J Cancer (1995) 0.95
The role of genetic variants of NOD2/CARD15, a receptor of the innate immune system, in GvHD and complications following related and unrelated donor haematopoietic stem cell transplantation. Int J Immunogenet (2008) 0.94
Human hematopoietic cell transplantation results in generation of donor-derived epithelial cells. Leukemia (2005) 0.94
Development and evaluation of assays for the determination of total and pancreatic amylase at 37 degrees C according to the principle recommended by the IFCC. Clin Biochem (2001) 0.92
Constitutive expression of the Wilms tumor suppressor gene (WT1) in renal cell carcinoma. Int J Cancer (1998) 0.92
Transplantation of peripheral blood progenitor cells from HLA-identical sibling donors. European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol (1996) 0.92
Fermi-LAT observations of the gamma-ray burst GRB 130427A. Science (2013) 0.91
Tumor-induced suppression of T lymphocyte proliferation coincides with inhibition of Jak3 expression and IL-2 receptor signaling: role of soluble products from human renal cell carcinomas. J Immunol (1997) 0.91
Patients with acute lymphoblastic leukaemia allografted with a matched unrelated donor may have a lower survival with a peripheral blood stem cell graft compared to bone marrow. Bone Marrow Transplant (2003) 0.89
Interferon-gamma and CXC chemokine induction by interleukin 12 in renal cell carcinoma. Clin Cancer Res (1999) 0.89
Characterization of the serological response in man to the latent membrane protein and the six nuclear antigens encoded by Epstein-Barr virus. J Gen Virol (1988) 0.89
Reduced-intensity conditioning with fludarabine and thiotepa for second allogeneic transplantation of relapsed patients with AML. Bone Marrow Transplant (2013) 0.89
Complete remission of Crohn's disease after high-dose cyclophosphamide and autologous stem cell transplantation. Bone Marrow Transplant (2003) 0.89
High-dose chemotherapy and autologous peripheral blood stem cell transplantation in adult patients with high-risk or advanced Ewing and soft tissue sarcoma. J Cancer Res Clin Oncol (2006) 0.88
[Diagnosis of and therapy for gastric cancer--work-flow]. Zentralbl Chir (2009) 0.87
The impact of HLA matching on long-term transplant outcome after allogeneic hematopoietic stem cell transplantation for CLL: a retrospective study from the EBMT registry. Leukemia (2010) 0.87
Bone marrow or peripheral blood stem cell transplantation from unrelated donors in adult patients with acute myeloid leukaemia, an Acute Leukaemia Working Party analysis in 2262 patients. J Intern Med (2012) 0.86
Induction of graft versus malignancy effect after unrelated allogeneic PBSCT using donor lymphocyte infusions derived from frozen aliquots of the original graft. Bone Marrow Transplant (2011) 0.86
Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin's lymphoma. Ann Oncol (2012) 0.86
Tumor-derived macrophage migration inhibitory factor promotes an autocrine loop that enhances renal cell carcinoma. Oncogene (2012) 0.86
Low-dose octreotide treatment is not effective in patients with advanced pancreatic cancer. Pancreas (1993) 0.86
Feasibility and response to budesonide as topical corticosteroid therapy for acute intestinal GVHD. Bone Marrow Transplant (1999) 0.86
High-versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34(+) immunoselection. J Clin Oncol (1999) 0.85
CT60 single-nucleotide polymorphism as a surrogate marker for donor lymphocyte infusion outcome after allogeneic cell transplantation for acute leukemia. Bone Marrow Transplant (2011) 0.85
ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML). Bone Marrow Transplant (2003) 0.84
Late cytomegalovirus polyradiculopathy following haploidentical CD34+-selected hematopoietic stem cell transplantation. Bone Marrow Transplant (2004) 0.84
Phase I trial of subcutaneous recombinant macrophage colony-stimulating factor: clinical and immunomodulatory effects. J Clin Oncol (1994) 0.83
Range finding using frequency-modulated laser diode. Appl Opt (1986) 0.83
In vitro and in vivo effects of synthetic ribozymes targeted against BCR/ABL mRNA. Leukemia (1993) 0.83
TIL from renal-cell carcinoma: restimulation with tumor influences proliferation and cytolytic activity. Int J Cancer (1990) 0.83
Polyethylene glycol conjugated interleukin-2: clinical and immunologic effects in patients with advanced renal cell carcinoma. Invest New Drugs (1994) 0.82
Influence of recombinant human granulocyte colony-stimulating factor (filgrastim) on hematopoietic recovery and outcome following allogeneic bone marrow transplantation (BMT) from volunteer unrelated donors. Bone Marrow Transplant (1999) 0.82
A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation. Bone Marrow Transplant (2008) 0.82
[Circulatory changes during lumbar puncture and pneumencephalography (as evaluated by ophthalmodynamography)]. Dtsch Z Nervenheilkd (1970) 0.81
Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy. J Clin Oncol (1992) 0.81
Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect. Leukemia (1997) 0.81
Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects. Cancer Res (1989) 0.81
High-dose methotrexate in patients with primary central nervous system lymphoma: does drug exposure really matter? Leuk Lymphoma (2011) 0.81
Evidence for a graft-versus-mast-cell effect after allogeneic bone marrow transplantation. Bone Marrow Transplant (2004) 0.81
[Aspergillus antigen detection: comparison of a new sandwich ELISA with the latex agglutination test in patients with histologically proven invasive aspergillosis]. Mycoses (1998) 0.80
Transport properties and growth parameters of PdC and WC nanowires prepared in a dual-beam microscope. Nanotechnology (2007) 0.80
Phase II trial of interleukin-2 and interferon-alpha in patients with renal cell carcinoma: clinical results and immunologic correlates of response. J Immunother (1997) 0.80
Effect of the EBNA-2 gene on the surface antigen phenotype of transfected EBV-negative B-lymphoma lines. Int J Cancer (1990) 0.80